TDC DrugSyn (OncoPolyPharm + DrugComb_NCI60)
Drug combination synergy benchmark (NCI ALMANAC + OncoPolyPharmacology).
Composite score: 77.0
Rubric (1–5 per criterion)
rigor
4/5
coverage
3/5
maintenance
4/5
adoption
4/5
quality
4/5
accessibility
5/5
industry_relevance
3/5
Metadata
Stages
Developmental CandidateLead ID / ADMET
Modalities
small-molecule
Task types
drug-synergy
License
MIT
First release
2021-02
Last updated
2024-12
Flags
none
Size & scope
- combos: 23000
- cell_lines: 60
Primary paper
Title
Therapeutics Data Commons
Authors
Huang K, Fu T, et al.
Year
2021
DOI / arXiv
Citations
620
Links
- Official site: https://tdcommons.ai/multi_pred_tasks/drugsyn/
- GitHub: https://github.com/mims-harvard/TDC
- Leaderboard: N/A
Hosted by (initiatives)
Experts (primary authors / maintainers)
Groups (host labs / companies / consortia)
Related benchmarks
Notes (honest caveats)
Important for combination therapy design.